Invention Grant
US09328156B2 Use of chimeric antigen receptor-modified T cells to treat cancer
有权
使用嵌合抗原受体修饰的T细胞治疗癌症
- Patent Title: Use of chimeric antigen receptor-modified T cells to treat cancer
- Patent Title (中): 使用嵌合抗原受体修饰的T细胞治疗癌症
-
Application No.: US14107302Application Date: 2013-12-16
-
Publication No.: US09328156B2Publication Date: 2016-05-03
- Inventor: Carl H. June , Bruce L. Levine , David L. Porter , Michael D. Kalos , Michael C. Milone
- Applicant: The Trustees of the University of Pennsylvania
- Applicant Address: US PA Philadelphia
- Assignee: The Trustees of the University of Pennsylvania
- Current Assignee: The Trustees of the University of Pennsylvania
- Current Assignee Address: US PA Philadelphia
- Agency: Saul Ewing LLP
- Agent Kathryn Doyle; Kelly J. Morgan
- Main IPC: C12N5/071
- IPC: C12N5/071 ; C12N5/0783 ; C12N5/22 ; A61K35/14 ; A61K39/00 ; C07K14/705 ; A61K35/17 ; A61K39/395 ; C07K16/28 ; C12N15/85
Abstract:
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Public/Granted literature
- US20140106449A1 Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer Public/Granted day:2014-04-17
Information query
